Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

HIV employs multiple means to evade the humoral immune response, particularly the
elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies …

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …

Complement activation by antibodies bound to pathogens, tumors, and self antigens is a
critical feature of natural immune defense, a number of disease processes, and …

Traditionally, vaccines have been developed by cultivating infectious agents and isolating
the inactivated whole pathogen or some of its purified components. 20 years ago, reverse …

Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical
development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies …

Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of
HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART …

Human immunodeficiency virus type 1 (HIV-1)-specific monoclonal antibodies with
extraordinary potency and breadth have recently been described. In humanized mice …

Broadly neutralizing antibodies against highly variable viral pathogens are much sought
after to treat or protect against global circulating viruses. Here we probed the neutralizing …